Advanced Enzyme Technologies (ADVENZYMES) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 saw steady operating performance with consolidated revenue of INR 1,691 million, up 5% year-over-year and 16% sequentially, with adjusted growth at 5% after accounting for delayed revenue recognition from Q2.

• EBITDA for Q3 was INR 553 million, up 3% year-over-year and 30% sequentially, with a margin of 33%. PAT margin stood at 23%.

• Standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2024, were reviewed and approved, with auditors expressing unmodified conclusions.

• The company operates solely in the 'manufacturing and sales of enzymes' segment.

• Management remains optimistic about future growth, driven by innovation, R&D, and a strong product pipeline, especially in the U.S. and nutraceutical sectors.

Financial highlights

• Consolidated Q3 revenue: INR 1,691 million (+5% YoY, +16% QoQ); adjusted for delayed sales, revenue is INR 1,610 million (+5% QoQ).

• EBITDA: INR 553 million (+3% YoY, +30% QoQ); EBITDA margin 33%.

• PAT: INR 389 million (+16% QoQ); PAT margin 23%.

• YTD consolidated revenue: INR 4,940 million (flat YoY); YTD PAT: INR 1,072 million (flat YoY).

• Gross margin stable at 77%.

Outlook and guidance

• Management expects only single-digit growth for FY25, with more detailed guidance for FY26 to be provided after budgeting.

• Growth pillars identified as biocatalysts, human nutrition, food, and animal feed segments.

• U.S. market seen as a key opportunity, with brand recognition and customer stickiness improving.

• Uncertainty remains due to global economic and political factors, especially in the U.S.

• Continued focus on core enzyme business and international subsidiaries.